Natco Pharma Increases Investment in US Biotech Firm eGenesis to $22 Million
Natco Pharma announced an additional investment of USD 14 million in US-based biotechnology firm eGenesis Inc through its subsidiaries, raising its total investment to USD 22 million. The funding, via convertible promissory notes, supports eGenesis's genome engineering efforts to develop transplantable organs, including kidney, liver, and heart transplants. eGenesis recently conducted the world's first porcine kidney transplant in humans under USFDA authorization. Natco Pharma's stock declined 1.5% following the announcement, with the transaction expected to complete by September 30.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 44/100.
Outlets measured: businessstandard, news18, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 25 Aug, 07:53 am. Other outlets followed.